In conclusion, this study identifies FGFR4 as a critical driver of lipid metabolic reprogramming in CRC and demonstrates that ISL effectively inhibits this axis, suppressing tumor progression (Figure 5). This evidence concerns the gene FGFR4 and neoplasm.